ABOUT US

Microbiome Medicine Center (MMC) is a microbiome research institute established by Southern Medical University and Zhujiang Hospital. MCC aims to uncover the underlying mechanisms in microbiome-host interactions as well as translating those knowledges into novel clinical diagnostic and treatment approaches. In the past three years, MMC has made a series of progresses studying the role of microbiome in disease diagnostic models, metabolic diseases and perinatal diseases and these works have been published in Cell, Nature Medicine (cover story), Gut (cover story), Journal of Hepatology, Microbiome and etc.

Postdoctoral positions are available now, and indefinitely, in MMC. MMC is interested in the role of microbiome in aging related diseases, metabolic diseases, stroke, cancer, maternal and infant's health, infectious diseases as well as in multi-omics data analysis, bioinformatics and disease diagnosis. Accordingly, MMC has a complete set of apparatus facilitating microbiome researches, including platforms for microbiome sample processing, big data analysis high-performance cluster, human studies, animal and functional experiments, microbes isolation and etc.

NEWS

MMC Hongwei Zhou's team makes progress in the bidirectional interaction between stroke and intestinal flora

2021-03-03
Recently, the studies paid for with Professor Zhou HongWei's team and Yin's team have revealed the two-way interaction between stroke and intestinal flora disorders. Ischemic stroke will quickly cause intestinal flora disorders and excessive growth of Enterobacteriaceae bacteria, which in turn will aggravate cerebral infarction. This study provides a new idea with translational value for clinic...

2023 Lion Lake Microbiome Medicnine Conference

2023-07-06

Prof. Zhou Hongwei received NSFC funding for the program“Basic Research on the Origin, Pathogenesis and Prevention of COVID-19”.

2020-03-18
The National Natural Science Foundation of China (NSFC) announced the list of projects funded by its basic research program to study the origin, pathogenesis and prevention of COVID-19. Prof. Zhou Hongwei was funded with the project titled 'Study of the early serological biomarkers for the 2019-nCoV (SARS-CoV-2) Infection'. The project was approved with a funding of 1.4 million RMB for 2 years....
请输入文本内容

March 3, 2021

MMC Hongwei Zhou's team makes progress in the bidirectional interaction between stroke and intestinal flora

Recently, the studies paid for with Professor Zhou HongWei's team and Yin's team have revealed the two-way interaction between stroke and intestinal flora disorders. Ischemic stroke will quickly cause intestinal flora disorders and excessive growth of Enterobacteriaceae bacteria, which in turn will aggravate cerebral infarction. This study provides a new idea with translational value for clinic...

March 18, 2020

Prof. Zhou Hongwei received NSFC funding for the program“Basic Research on the Origin, Pathogenesis and Prevention of COVID-19”.

The National Natural Science Foundation of China (NSFC) announced the list of projects funded by its basic research program to study the origin, pathogenesis and prevention of COVID-19. Prof. Zhou Hongwei was funded with the project titled 'Study of the early serological biomarkers for the 2019-nCoV (SARS-CoV-2) Infection'. The project was approved with a funding of 1.4 million RMB for 2 years....

February 19, 2020

Prof. Zhou Hongwei shared diagnosis experience of COVID-19 at live broadcast.

Prof. Zhou Hongwei is the Director of Division of Laboratory Medicine, Zhujiang Hospital of Southern Medical University and the Vice Chairman of Laboratory Medicine branch of Guangdong Medical Association. Research directions and achievements: Prof. Zhou Hongwei and his team committed to understand the host-associated microbes (intestine, oral cavity, reproductive tract, etc.) to understand the...